No 02 2022

Presentations at the Alzheimer's Association International Conference (AAIC) show a field moving rapidly forward both with regard to treatments and diagnostics. 

Maria Ekdahl brings more than 20 years of senior finance leadership experience, including her current role as CFO of Nasdaq Stockholm-listed pharmaceutical company, Infant Bacterial Therapeutics, and will join Biovica on October 14, 2026.

Navinci Diagnostics has initiated a pilot project together with Lumito to evaluate the possibilities of combining the companies’ respective technologies within advanced tissue analysis.

BioArctic’s partner Eisai has announced that the US Food and Drug Administration (FDA) has approved a supplemental Biologics License Application (sBLA) for a once weekly lecanemab irmb subcutaneous injection (US brand name: Leqembi Iqlik) as a starting dose for the treatment of early Alzheimer’s disease.

Both the detection of pyrogens in general and that of bacterial endotoxins in particular are undergoing a period of transition.

AstraZeneca has entered into an exclusive license agreement with Dizal Pharmaceutical for Zegfrovy (sunvozertinib), a novel oral irreversible epidermal growth factor receptor (EGFR) inhibitor for patients with lung cancer.

Evaxion has presented new data further supporting the multi-component concept of its cytomegalovirus (CMV) vaccine program EVX-V1.